Assetmark Inc. Purchases 43,436 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Assetmark Inc. increased its stake in IQVIA by 33.6%, buying 43,436 shares to hold 172,625 shares (about 0.10% of the company) worth $38.91 million.
• IQVIA beat the quarter with $3.42 EPS vs. $3.40 expected and $4.36B revenue (+10.3% YoY), set FY2026 EPS guidance of 12.550–12.850, and carries an average analyst "Buy" rating with a $226.63 target.

Assetmark Inc. grew its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 33.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 172,625 shares of the medical research company's stock after acquiring an additional 43,436 shares during the quarter. Assetmark Inc. owned 0.10% of IQVIA worth $38,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of IQV. Transcend Capital Advisors LLC raised its stake in IQVIA by 8.8% during the fourth quarter. Transcend Capital Advisors LLC now owns 2,143 shares of the medical research company's stock valued at $483,000 after purchasing an additional 174 shares in the last quarter. Choreo LLC lifted its holdings in shares of IQVIA by 4.7% in the 4th quarter. Choreo LLC now owns 5,266 shares of the medical research company's stock valued at $1,199,000 after acquiring an additional 236 shares during the last quarter. Dara Capital US Inc. purchased a new position in IQVIA in the fourth quarter worth about $166,000. Sumitomo Mitsui Trust Group Inc. lifted its position in IQVIA by 41.6% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,132,072 shares of the medical research company's stock worth $255,180,000 after buying an additional 332,505 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its stake in IQVIA by 3.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 181,263 shares of the medical research company's stock worth $40,858,000 after purchasing an additional 5,389 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 1.9%

IQVIA stock opened at $175.34 on Wednesday. The firm has a market cap of $29.76 billion, a PE ratio of 22.31, a P/E/G ratio of 1.67 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock's 50 day simple moving average is $171.63 and its two-hundred day simple moving average is $204.25. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to analysts' expectations of $4.24 billion. During the same quarter in the previous year, the company earned $3.12 earnings per share. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

IQV has been the subject of several research reports. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a "buy" rating for the company in a research report on Friday, February 6th. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a "buy" rating on the stock in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They issued an "outperform" rating and a $221.00 target price for the company. Truist Financial lowered their price target on shares of IQVIA from $290.00 to $245.00 and set a "buy" rating on the stock in a report on Thursday, February 19th. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $255.00 to $225.00 and set an "overweight" rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $226.63.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.